Description

The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:

• Direct-acting, small-molecule antiviral agents such as   molnupiravir, nirmatrelvir + ritonavir, and remdesivir
• Monoclonal antibody treatments such as bamlanivimab + etesevimab, casirivimab + imdevimab, cilgavimab + tixagevimab, regdanvimab, and sotrovimab

Presenter:

Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Review the downloadable slidesets at:
https://bit.ly/3FXc90w
https://bit.ly/32tp2BT

Link to full program: 
https://bit.ly/3Ix8uZg

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.